RxDoctor Payments Data

Paul Carter, PA

Medical · Philadelphia, PANPI 1639205792

Payments from drug & device makers

$10,235in general payments, 2019–2025

Across 543 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • GSK$927
  • Exact Sciences$471
  • Biohaven Pharmaceuticals, Inc.$471
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,235100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,235 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,380
Medicare patients
161
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$80,359
OzempicSemaglutide51$48,604
JanuviaSitagliptin Phosphate30$42,036
FarxigaDapagliflozin Propanediol43$41,501
JardianceEmpagliflozin40$32,684
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,385
RybelsusSemaglutide15$23,607
XareltoRivaroxaban20$22,347
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$10,629
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,294
MyrbetriqMirabegron12$7,133
Incruse ElliptaUmeclidinium Bromide18$6,689
BrilintaTicagrelor14$6,048
Rosuvastatin Calcium278$5,660
Novolog FlexpenInsulin Aspart35$5,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$308$80,359101 claims
Novo NordiskOzempic, Rybelsus$1,043$72,21166 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,006$56,84272 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$927$47,44877 claims
MerckJanuvia$81$42,03630 claims
Boehringer IngelheimJardiance$316$32,68440 claims
Johnson & JohnsonXarelto$42$22,34720 claims
Astellas Pharma US IncMyrbetriq$159$7,13312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →